GeneDx Holdings Corp.

NasdaqGS WGS

GeneDx Holdings Corp. Free Cash Flow Yield on February 06, 2025: -3.51%

GeneDx Holdings Corp. Free Cash Flow Yield is -3.51% on February 06, 2025, a 98.11% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

GeneDx Holdings Corp. 52-week high Free Cash Flow Yield is -2.14% on January 07, 2025, which is 39.07% above the current Free Cash Flow Yield.
GeneDx Holdings Corp. 52-week low Free Cash Flow Yield is -187.82% on February 07, 2024, which is -5,247.92% below the current Free Cash Flow Yield.
GeneDx Holdings Corp. average Free Cash Flow Yield for the last 52 weeks is -26.82%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqGS: WGS

GeneDx Holdings Corp.

CEO	Ms. Katherine A. Stueland
IPO Date	Nov. 4, 2020
Location	United States
Headquarters	North Tower
Employees	1,000
Sector	Healthcare
Industries Telehealth Artificial Intelligence (AI) Autonomous Driving Big Data Biotechnology Clinical Trials Pharmaceuticals Robotics

Description

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Key trends

Past 5 years